Description
AMBLE · RESEARCH PRODUCT INFORMATION
Product overview
Pinealon is the synthetic tripeptide glutamic acid-aspartic acid-arginine. The source discusses cellular regulation and neurobiological research. The product is not presented as a cognitive-enhancement product, an anti-aging therapy or a treatment for neurological disease.
For scientific research and development only. Intended for in-vitro laboratory work, not human or animal administration. Not for use as a medicine, diagnostic product, medical device, food, supplement or cosmetic. No dosing, injection or treatment instructions are provided.
Product specifications
| Quantity | 10 mg |
|---|---|
| Unit | 1 vial |
| Physical Appearance | White powder |
| Salt form | Acetate |
| Supplier reference purity (not lot verification) | ≥98% |
| Sequence | Glu-Asp-Arg |
| Source-reported molecular mass (units not stated) | 418.4 |
| CAS NO. | 175175-23-2 |
| Source-listed laboratory solvents | Bacteriostatic water |
Product features
- Source-listed pack: 10 mg 1 vial
- Source-listed presentation: White powder
These characteristics identify the supplier reference presentation. They are not independent testing or verification of the current Amble lot.
These are reference specifications reported on the corresponding Particle Peptides page, not independent analytical verification of an Amble lot. Confirm the received label, identity, formulation and batch documentation before laboratory use. Unlisted fields have not been invented.
Storage and handling
1. Research use and restrictions
For scientific research and development only. Intended for in-vitro laboratory work, not human or animal administration. Not for use as a medicine, diagnostic product, medical device, food, supplement or cosmetic. No dosing, injection or treatment instructions are provided.
Literature involving animals or clinical studies is background information only and does not authorize this product for those uses. Do not supply this material for human investigational use.
2. Peptides in transport
Follow the current product label and lot-specific transport documentation. A general supplier statement about transport stability is not a guarantee for every formulation, liquid, blend or Amble shipment. The source supplier lists shipping restrictions for: Canada, Croatia, Czech Republic, Iceland, Ireland, Luxemburg, Norway, Serbia, Switzerland. This is the supplier’s published list, not a complete legal assessment or a replacement for Amble’s shipping policy.
3. Storage of lyophilized peptides
The supplier gives general guidance to protect lyophilized peptides from light and moisture. Storage temperature and expiry must follow the actual formulation and lot documentation. Do not treat a generic storage-duration table as validated shelf-life data for this Amble product.
4. Storage of reconstituted peptides
Solution stability depends on sequence, formulation, solvent and handling. Use product-specific stability documentation and laboratory procedures rather than assuming the same refrigerated life for all peptides. The supplier’s Ipamorelin stability discussion cannot be extrapolated to other products without supporting data.
5. Storage of peptide solutions
Avoid unnecessary freeze–thaw cycling and follow the documented conditions for the exact solution. This page does not establish a validated shelf life after preparation. The listed solvent information is a supplier reference, not a patient-use or injection protocol.
Overview of published research
The corresponding source page discusses the topics below. They describe areas of investigation, not proven customer benefits, treatment indications or evidence that this particular Amble batch has been tested.
- Gene regulation and cellular responses
- Neuronal and oxidative-stress models
- Experimental aging and circadian research
Interpretation depends on the study design, experimental material and model. The presence of a publication in a supplier bibliography is not an independent verification of the supplier’s interpretation or a guarantee of safety or effectiveness. No clinical doses or administration protocols are reproduced here.
Quality and documentation
Source attribution: the specifications and bibliography below refer to Particle Peptides. Amble branding does not turn the supplier’s studies or documents into Amble batch certifications.
View the corresponding supplier product page
- Supplier safety data sheet (MSDS)
- Supplier COA/test document — not verification of the current Amble lot
Document links are retained as supplier references. Confirm lot matching, document authenticity and applicability before relying on them; this update does not independently verify those documents.
Bibliography listed by the supplier (13 entries)
Bibliographic entries are attributed to the source page. Individual citations have not all been independently validated; consult the original publications and distinguish primary studies from secondary reports.
- L. I. Fedoreyeva, I. I. Kireev, V. K. Khavinson, and B. F. Vanyushin, “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA,” Biochem. Biokhimiia, vol. 76, no. 11, pp. 1210–1219, Nov. 2011.
- V. N. Meshchaninov, E. L. Tkachenko, S. V. Zharkov, I. V. Gavrilov, and I. E. Katyreva, “[EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION],” Adv. Gerontol. Uspekhi Gerontol., vol. 28, no. 1, pp. 62–67, 2015.
- V. K. Khavinson, B. I. Kuznik, S. I. Tarnovskaya, and N. S. Lin’kova, “Short Peptides and Telomere Length Regulator Hormone Irisin,” Bull. Exp. Biol. Med., vol. 160, no. 3, pp. 347–349, Jan. 2016.
- K. S. Rana et al., “Plasma irisin levels predict telomere length in healthy adults,” Age Dordr. Neth., vol. 36, no. 2, pp. 995–1001, Apr. 2014.
- A. Arutjunyan, L. Kozina, S. Stvolinskiy, Y. Bulygina, A. Mashkina, and V. Khavinson, “Pinealon protects the rat offspring from prenatal hyperhomocysteinemia,” Int. J. Clin. Exp. Med., vol. 5, no. 2, pp. 179–185, 2012.
- V. Khavinson et al., “Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes,” Rejuvenation Res., vol. 14, no. 5, pp. 535–541, Oct. 2011.
- L. S. Kozina, “[Investigation of antihypoxic properties of short peptides],” Adv. Gerontol. Uspekhi Gerontol., vol. 21, no. 1, pp. 61–67, 2008.
- J. Zhang and W. Zhang, “Can irisin be a linker between physical activity and brain function?,” Biomol. Concepts, vol. 7, no. 4, pp. 253–258, Aug. 2016.
- V. K. Khavinson, N. S. Lin’kova, S. I. Tarnovskaya, R. S. Umnov, E. V. Elashkina, and A. O. Durnova, “Short peptides stimulate serotonin expression in cells of brain cortex,” Bull. Exp. Biol. Med., vol. 157, no. 1, pp. 77–80, May 2014.
- A. M. Mendzheritskiĭ, G. V. Karantysh, G. A. Ryzhak, and S. V. Dem’ianenko, “[Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon],” Adv. Gerontol. Uspekhi Gerontol., vol. 27, no. 1, pp. 94–97, 2014.
- “Serum Caspase-3 p17 Fragment Is Elevated in Patients With ST-Segment Elevation Myocardial Infarction | JACC: Journal of the American College of Cardiology.” [Online]. Available: http://www.onlinejacc.org/content/57/2/220. [Accessed: 11-Jun-2019].
- M. A. Voicekhovskaya, N. I. Chalisova, E. A. Kontsevaya, and G. A. Ryzhak, “Effect of bioregulatory tripeptides on the culture of skin cells from young and old rats,” Bull. Exp. Biol. Med., vol. 152, no. 3, pp. 357–359, Jan. 2012.
- A. S. Bashkireva and V. G. Artamonova, “[The peptide correction of neurotic disorders among professional truck-drivers],” Adv. Gerontol. Uspekhi Gerontol., vol. 25, no. 4, pp. 718–728, 2012.
Product questions and answers
What is Pinealon 10mg?
Pinealon is the synthetic tripeptide glutamic acid-aspartic acid-arginine. The source discusses cellular regulation and neurobiological research. The product is not presented as a cognitive-enhancement product, an anti-aging therapy or a treatment for neurological disease.
What quantity is listed for Pinealon 10mg?
The corresponding supplier reference lists 10 mg 1 vial. This applies to the stated presentation only; other strengths and quantities are not included.
Which identity or formulation details matter for Pinealon 10mg?
The supplier provides 9 reference specification fields for this listing. Those fields and source documents are not an independent Amble batch certificate.
Does the linked documentation certify this Amble batch?
No Amble-lot certification is established by a supplier webpage or an unmatched COA. Confirm the laboratory report, exact batch number, identity and formulation before relying on the documentation.
What storage conditions are verified for Pinealon 10mg?
Follow the actual lot label and product-specific safety and stability documentation. Generic storage tables and studies on another peptide do not establish this product’s shelf life.
Is Pinealon 10mg intended for human use?
No. This is a research-use listing for in-vitro laboratory work, not human or animal administration. The page provides no dosing, injection or treatment instructions.
US online ordering information
Information for customers reviewing Pinealon 10mg online from the United States.
This is a research-use listing, not a patient treatment or a finished medicine. Do not use it for human or animal administration. Review the exact formulation and lot-matched documentation, and confirm jurisdiction-specific eligibility before placing any order.
Use the live price and stock display on this page and review the final checkout total. Delivery, tax and return conditions depend on the product and destination; do not assume a delivery date or eligibility from this page alone.
For product or ordering questions, email hello@joinamblehealth.com. Read the Amble terms of service or visit your Amble account.
Reviews
There are no reviews yet.